| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8633297 | Neuropeptides | 2018 | 6 Pages |
Abstract
AP102 is a new SSA that better reduces signaling at SSTR2 than SSTR5 and prevents cell proliferation at both receptors. The euglycaemic effect of AP102 observed in preclinical studies may be related to this intermediate agonistic potency between pasireotide and octreotide at SSTR2 and SSTR5.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Jeremy Streuli, Alan G. Harris, Cecilia Cottiny, Florent Allagnat, Adrian F. Daly, Eric Grouzmann, Karim Abid,